HIGHLIGHTS
- who: Krisztian Homicsko and collaborators from the Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland Department of Dermatology, Medical University of Vienna, Vienna, Austria have published the research work: Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma, in the Journal: (JOURNAL)
- what: The aim of the statistical analysis was to evaluate the prognostic and predictive ability of baseline PPI use in patients who participated in CheckMate 066, 067, or 069. Kaplan-Meier analysis of the dacarbazine and ipilimumab arms of ipilimumab arms of the studies showed no discernible . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.